Gilead Sciences, Inc. (NASDAQ:GILD) Position Boosted by Traynor Capital Management Inc.

Traynor Capital Management Inc. raised its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 12.8% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 28,290 shares of the biopharmaceutical company’s stock after buying an additional 3,210 shares during the quarter. Gilead Sciences accounts for about 1.1% of Traynor Capital Management Inc.’s holdings, making the stock its 21st biggest position. Traynor Capital Management Inc.’s holdings in Gilead Sciences were worth $2,289,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently added to or reduced their stakes in GILD. FMR LLC increased its position in Gilead Sciences by 1.1% in the 2nd quarter. FMR LLC now owns 23,037,303 shares of the biopharmaceutical company’s stock valued at $1,630,581,000 after acquiring an additional 258,005 shares in the last quarter. Seizert Capital Partners LLC boosted its stake in shares of Gilead Sciences by 4.6% in the 1st quarter. Seizert Capital Partners LLC now owns 632,574 shares of the biopharmaceutical company’s stock valued at $42,964,000 after purchasing an additional 27,547 shares during the last quarter. Investment Centers of America Inc. boosted its stake in shares of Gilead Sciences by 7.2% in the 1st quarter. Investment Centers of America Inc. now owns 29,064 shares of the biopharmaceutical company’s stock valued at $1,979,000 after purchasing an additional 1,958 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of Gilead Sciences by 2.4% in the 2nd quarter. Vanguard Group Inc. now owns 92,841,960 shares of the biopharmaceutical company’s stock valued at $6,571,355,000 after purchasing an additional 2,148,697 shares during the last quarter. Finally, Northern Trust Corp boosted its stake in shares of Gilead Sciences by 0.7% in the 2nd quarter. Northern Trust Corp now owns 16,430,476 shares of the biopharmaceutical company’s stock valued at $1,162,949,000 after purchasing an additional 116,780 shares during the last quarter. Hedge funds and other institutional investors own 75.94% of the company’s stock.

Gilead Sciences, Inc. (GILD) opened at $79.06 on Friday. The company has a debt-to-equity ratio of 1.10, a current ratio of 3.68 and a quick ratio of 3.56. Gilead Sciences, Inc. has a twelve month low of $63.76 and a twelve month high of $86.27. The stock has a market capitalization of $103,250.00, a price-to-earnings ratio of 8.99, a P/E/G ratio of -1.58 and a beta of 1.13.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Thursday, October 26th. The biopharmaceutical company reported $2.27 EPS for the quarter, topping the consensus estimate of $2.13 by $0.14. The business had revenue of $6.51 billion during the quarter, compared to the consensus estimate of $6.40 billion. Gilead Sciences had a return on equity of 57.15% and a net margin of 42.22%. The firm’s revenue was down 13.2% compared to the same quarter last year. During the same quarter last year, the company earned $2.75 EPS. analysts predict that Gilead Sciences, Inc. will post 8.53 earnings per share for the current year.

The firm also recently declared a quarterly dividend, which was paid on Thursday, December 28th. Stockholders of record on Friday, December 15th were given a dividend of $0.52 per share. The ex-dividend date was Thursday, December 14th. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.63%. Gilead Sciences’s dividend payout ratio (DPR) is presently 23.66%.

GILD has been the topic of several recent analyst reports. Berenberg Bank set a $96.00 price objective on shares of Gilead Sciences and gave the stock a “buy” rating in a research note on Thursday, October 19th. Royal Bank of Canada assumed coverage on shares of Gilead Sciences in a research note on Thursday, September 14th. They issued an “outperform” rating and a $94.00 price target on the stock. JPMorgan Chase & Co. set a $85.00 price target on shares of Gilead Sciences and gave the company a “buy” rating in a research note on Wednesday, October 25th. Credit Suisse Group reiterated a “buy” rating and issued a $82.00 price objective on shares of Gilead Sciences in a report on Thursday, December 7th. Finally, Zacks Investment Research downgraded shares of Gilead Sciences from a “hold” rating to a “sell” rating in a report on Wednesday, December 27th. Two investment analysts have rated the stock with a sell rating, thirteen have issued a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $85.03.

In related news, EVP Gregg H. Alton sold 15,000 shares of the company’s stock in a transaction on Wednesday, November 1st. The stock was sold at an average price of $74.82, for a total value of $1,122,300.00. Following the sale, the executive vice president now directly owns 77,363 shares of the company’s stock, valued at $5,788,299.66. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider John F. Milligan sold 220,000 shares of the business’s stock in a transaction on Monday, November 13th. The stock was sold at an average price of $72.88, for a total value of $16,033,600.00. The disclosure for this sale can be found here. In the last quarter, insiders have sold 461,666 shares of company stock valued at $34,072,567. Corporate insiders own 1.30% of the company’s stock.

WARNING: “Gilead Sciences, Inc. (NASDAQ:GILD) Position Boosted by Traynor Capital Management Inc.” was published by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this news story on another domain, it was illegally stolen and republished in violation of US and international copyright & trademark laws. The original version of this news story can be accessed at https://stocknewstimes.com/2018/01/12/traynor-capital-management-inc-boosts-holdings-in-gilead-sciences-inc-gild.html.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply